ArticleFrontiers in immunology2021
A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure.Journal of molecular and cellular cardiology plus · 2026Article
- The NKp44-1 Isoform Is an Activating Receptor for PDGF-DD Expressed on Natural Killer Cells.Cancers · 2026Article
- Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities.Experimental hematology & oncology · 2025Review
- Article
- Regulation of KLRC and Ceacam gene expression by miR-141 supports cell proliferation and metastasis in cervical cancer cells.BMC cancer · 2024Article
- Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma.Apoptosis : an international journal on programmed cell death · 2024Article
- Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.European journal of medical research · 2024Article
- Radiogenomic landscape: Assessment of specific phagocytosis regulators in lower-grade gliomas.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- A novel immune-related gene signature for predicting immunotherapy outcomes and survival in clear cell renal cell carcinoma.Scientific reports · 2023Article
- Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.European journal of medical research · 2023Article
- Article
- Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organization.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Article
- Advances in NK cell therapy for brain tumors.NPJ precision oncology · 2023Review
- Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.Frontiers in immunology · 2023Article
- Platelet, a key regulator of innate and adaptive immunity.Frontiers in medicine · 2023Review
- A novel natural killer cell-related signatures to predict prognosis and chemotherapy response of pancreatic cancer patients.Frontiers in genetics · 2023Article
- PDGF-D-induced immunoproteasome activation and cell-cell interactions.Computational and structural biotechnology journal · 2023Article
- The role of angiogenic growth factors in the immune microenvironment of glioma.Frontiers in oncology · 2023Review
- The tumor micro-environment in pediatric glioma: friend or foe?Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The binding of platelet-derived growth factor D (PDGF-DD) to the NKp44 receptor activates a distinct transcriptional program in primary IL-2 expanded human natural killer (NK) cells. We were interested in knowing if the PDGF-DD-NKp44 pathway of NK cell activation might play a clinically relevant role in anti-tumor immunity. In order to address this question, we determined transcriptional signatures unique to resting, IL-2 expanded, and PDGF-DD activated, NK cells, in addition to different T cell subsets, and established the abundance of these immune cell phenotypes in The Cancer Genome Atlas (TCGA) low-grade glioma (LGG) dataset using CIBERSORT. Our results show that LGG patient tumors enriched for either the PDGF-DD activated NK cell or memory CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.